| Question |
Answer |
| MOA mannitol |
creates an osmotic diuresis because it can't leave the tubule inhibits Na and Cl reabsorption in PC and ascendin loop |
| clinical uses of mannitol |
to decrease intractranial pressure or intraocular pressure through volume depletion |
| side effects of mannitol |
can cause pulmonary edema d/t extracellular volume expansion, pulling water out of cells hypernatremia |
| contraindications of mannitol |
CHF pulmonary edema anuria severe renal failure severe dehydration |
| how is mannitol administered? |
parenterally (poorly absorbed PO) |
| MOA spironolactone |
K sparing diuretic, antagonizes aldosterone in the DCT, inhibiting Na reabsorption |
| what effect does spironolactone have on Ca |
decreases serum Ca levels by directly inhibiting its transport in the DCT |
| clinical uses of spironolactone |
HTN pulmonary edema edema from CHF or cirrhosis, nephrotic syndrome primary hyperaldosteronism |
| side effects of spironolactone |
gynecomastia (and other anti-androgenic effects) hyperkalemia hyponatremia hypochlroemic acidosis (blocks aldosterone's effect on Na/H antiporter) |
| MOA amiloride |
K sparing diuretic, directly inhibits Na reabsorption, independent of aldosterone increased Ca reabsorption |
| uses of amiloride |
treats ca stones |
| differences between amiloride and triamterene? |
MOA similar, but triampterene has shorter t1/2 |
| MOA furosemide |
loop diuretic, blocking NKCC increased urinary excretion of K, Mg, Ca increases RBF without altering GFR |
| clinical uses for furosemide |
edema to increase urine output in ARF (although it doesn't alter the course of ARF) hypercalcemia hyperkalemia |
| side effects of furosemide |
K wasting metabolic alkalosis Mg depletion ototoxicity hyperuricemia |
| why does hyperuricemia result from furosemide use? |
increases urate reabsorption d/t increased proximal Na reabsorption |
| contraindication of furosemide |
sulfa allergy |
| which is the only loop diuretic without a sulfa group? |
ethacrynic acid |
| MOA HCTZ? |
block NaCl transport at the DCT Enhanced Ca reaborption (because Na and Ca compete for ATP dependent reabsorption at DCT) |
| clinical uses of HCTZ? |
HTN edema DI (by inducing mild volume depletion) to stop recurrent renal calcium stones |
| contraindication of HCTZ |
sulfa allergy |
| side effects of HCTZ |
hyperglycemia hyperlipidemia hyperuricemia hypercalcemia melabolic alkalosis Mg depletion |
| MOA acetazolamide |
Carbonic anhydrase inhibitor so it inhibits the reabsorption of HCO3- in PCT also CA is in ciliary body of eye and in choroid plexus cells, so it decreases aqueous humor production and increases CSF production |
| uses for acetazolamide |
acute altitude sickness glaucoma treatment for alkalosis facilitate eexcretion of weak acid (as seen in tumor lysis syndrome) |
| side effects of acetazolamide |
encephalopathy (from decreased excretion of NH3 in urine) renal stones b/c calcium phosphate is less soluble in alkaline urine hyperchloremic metabolic acidosis |
| contraindications of acetazolamide |
sulfa allergy hepatic or renal dz hyperchloremic acidosis hyponatremia hypokalemia |
| what effect does furosemide have on the following serum levels: K HCO3 Ca Mg urate |
decreased increased decreased decreased increased |
| what effect does thiazide have on the following serum levels: K HCO3 Ca Mg urate |
decrease increase increased decreased increased |
| what effect does spironolactone have on the following serum levels: K HCO3 Ca Mg urate |
increased decreased decreased none none |
| what effect does amiloride have on the following serum levels: K HCO3 Ca Mg urate |
increased decreased increased none none |
| what effect does acetazolamide have on the following serum levels: K HCO3 Ca Mg urate |
decreased decreased none none none |
| which diuretics decrease Mg? |
furosemide HCTZ |
| which diuretics increase urate? |
furosemide HCTZ |
| contraindication of spironolactone |
acute renal failure |
| MOA nitroprusside |
vasodilation of arteries and veins contact with RBC --> decomposition of drug and release of NO NO, via activation of guanylate cyclase --> vasodilation |
| clinical uses of nitroprusside |
HTN crisis aortic dissection (must be given with B blocker) CHF |
| side effects of nitroprusside |
hypotension reflex tachy CN release |
| contraindications for nitroprusside |
known inadequate cerebral circulation hepatic/renal dz (increases thiocyanate toxicity) |
| MOA nitroglycerine |
via guanylate cyclase --> increase cGMP which activates cAMP protein dependent kinases and leads to dephosphorylation of myosin light chains and decreased intracellular Ca --> relaxation of veins and increased venous capacitance |
| uses of nitroglyceride |
treats angina (decresae coronary asospasm) CHF HTN |
| side effects of nitroglycerine |
hypotension, tachycardia, throbbing HA from meningeal arterial dilation |
| MOA captopril |
ACE inhibitor blocks formation of AII and degradation of bradykinin so, inhibits constriction of efferent arteriole, and potentiates vasodilation caused by bradykinin also causes venous vasodilation |
| uses of captopril |
HTN CHF ischemic heart disease decreases proteinuria and progression of nephropathy in diabetics |
| side effects of captopril |
cough from increased bradykinin can cause renal insufficiency b/c GFR is not increased in low volume states |
| contraindications of captopril |
renal insufficiency bilateral renal artery stenosis |
| MOA losartan |
AII receptor blocker |
| uses of losartan |
HTN CHF |
| side effects of losartan |
no cough can't maintain GFR by vasodilation of efferent arterioles |
| MOA milrinone |
inhibits PDE III --> dilation of arteries and veins PDE III inactivates cAMP, so this process is inhibited --> increased Ca reflux in myocardium, with increased cardiac contractility |
| uses of milrinone |
refractory CHF can increase mortality, and should ONLY be used if diuretics, digoxin, and vasodilators have failed a-fib |
| side effects of milrinone |
ventricular arrhythmias hypotension hepatotoxicity |
| MOA sildenafil |
blocks PDE V action (thus potentiating the action of cGMP dependent kinases that activate phosphatases that encourage the relaxation of smoooth muscle) also decreases the Ca concnetration --> smooth muscle relaxation |
| MOA digoxin |
blocks the Na-K pump --> increased Na intracellularly this inhibits the Na concentration gradient from forming, blocking the Ca from leaving the cells this improves cardiac contractility also slows the conduction through AV node |
| uses of digoxin |
CHF a fib, a flutter (slows conduction through AV node) |
| side effects of digoxin |
narrow therapeutic window visual disturbances, nausea, blurred vision a-tac and AV block can result |
| contraindication of digoxin |
hypokalemia 2nd/3rd degree heart block WPW who develop a-fib --> increased impulses through accessory pathway --> VF |
| what abnormalities can be seen on the EKG on a person taking digoxin |
incresaed PR, decreased QT, scooping of ST segments, T wave inversion |